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Abstract
Background: Various parts of Garcinia mangostana Linn., including its pericarp, have been traditionally used to
treat a variety of ailments. In an attempt to establish its medicinal value, the present study was carried out to
determine the hypoglycaemic potential of G. mangostana pericarp ethanolic extract (GME) using the
streptozotocin-induced (STZ) diabetic rats.
Methods: GME at 2,000 mg/kg was subjected to a single-dose acute toxicity test. Following this, the effect of GME
(50, 100, and 200 mg/kg) on blood glucose level of normoglycaemic and STZ-induced diabetic rats was determined
using single-dose (acute) and multiple-dose (subacute) approaches. Subsequent to the multiple-dose study, serum
biochemical analysis and liver histopathological examination were also performed. Throughout the experiments, the
effect of GME was compared against the standard hypoglycaemic drug, glibenclamide.
Results: GME was safe for oral consumption up to the dose of 2,000 mg/kg. In both single- and multiple-dose
studies, GME significantly (p < 0.05) reduced the blood glucose level in normoglycaemic rats and STZ-induced
diabetic rats when compared against the normal control group or diabetic control group, respectively. Moreover,
GME also significantly (p < 0.05) increased the rats’ body weight in comparison to the diabetic control group in the
multiple-dose study. GME also significantly (p < 0.05) reduced the levels of certain biochemical parameters [i.e.,
triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), very low density lipoprotein (VLDL), serum
glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), urea, and creatinine] while
increased the others [i.e., high density lipoprotein (HDL) and total protein (TP)] when compared to the diabetic
control group. Histopathological assessment of the collected liver revealed a mild increase in the population of
β-cells in the diabetic rats.
Conclusion: GME exerts the hypoglycaemic activity possibly by increasing the population of insulin-producing
β-cells. This activity could be attributed to the presence of antioxidant-bearing tannins like epicathecin, and
xanthones like α-mangostin. Thus, the findings demonstrated that GME could be a potential candidate in the
management of diabetes owing to its hypoglycaemic effect.
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Background
The number of diabetic mellitus (DM) cases is rapidly
increasing in recent years. According to the National
Diabetes Statistics Report [1], approximately 29.1 million
Americans, or 9.3 % of the population, had diabetes in
2012 with around 8.1 million of them were undiagnosed.
Moreover, there were about 3.3 million cases of diabetes
reported in Malaysia in 2015, according to the Inter-
national Diabetes Federation [2]. Diabetes mellitus is a
chronic disease characterised by the high blood glucose
levels as a result of impaired glucose metabolism. Im-
paired glucose metabolism occurs when the pancreas
does not produce enough insulin or when the body cannot
effectively use the insulin it produces [3]. Hyperglycaemia,
or raised blood sugar, is a general effect of uncontrolled
diabetes that eventually leads to severe damage to many of
the body’s systems, especially the nerves and blood vessels.
Elevated blood glucose triggers oxidative damage of cell
membranes through the production of superoxide anions,
which generate hydroxyl radicals via Haber-Weiss reac-
tion, inducing peroxidation of membrane lipids and pro-
tein glycation. These radicals further cause derangement
of major biomolecules including carbohydrate, protein,
lipid, and DNA [3]. Antioxidants play an important role in
the prevention of cell damage against reactive oxygen
species (ROS). Thus, herbal preparations containing
both antioxidants and hypoglycaemic properties would
be useful in diabetic management.
Garcinia mangostana Linn., generally known as man-
gosteen and belongs to the family Clusiaceae, is a tree
cultivated for centuries in the tropical rainforest. Its fruit
hull is used as phytomedicine in the Southeast Asia for
the treatment of skin and wound infection [4], inflam-
mation, diarrhoea [5], cholera, and dysentery [6]. Phyto-
chemical studies of G. mangostana extracts (GME)
report that this plant contains a variety of secondary me-
tabolites such as oxygenated and prenylated xanthones
[7]. Moreover, 50 xanthones have been identified in G.
mangostana [8]. The ethnopharmacological views of the
fruit rinds suggest remarkable properties such as antioxi-
dants [9], antitumour [10], anti-inflammatory [11], anal-
gesic [12], antiviral activities [13], cardioprotective
effects [14], antifungal [15], antiallergy [16], antibacterial
[17], antituberculosis [18], and immunomodulation [19].
Xanthone backbones of mangosteen have been reported as
a potent molecular basis for in vitro α-glucosidase inhib-
ition and proven to reduce postprandial hyperglycaemic
condition by suppressing the glucose absorption [20]. The
extract of G. mangostana has also been reported to retard
glucose absorption through inhibition of carbohydrate-
hydrolysing enzymes such as α-glucosidase and α-amylase
[21]. The major component of the extract, α-mangostin,
demonstrates a protective role in sexual dysfunction and
exerts an antidiabetic effect in streptozotocin-induced
diabetic male rats possibly via the reduction of blood glu-
cose levels [22]. Preliminary studies in our laboratory indi-
cated potent antioxidant and hypoglycaemic effects of
crude ethanolic extracts on normoglycaemic models in rats.
Hence, the present study was performed to evaluate the
hypoglycaemic efficacy of crude ethanolic extracts of GME
on the normal and streptozotocin-induced diabetic rats.
Methods
Plant identification
Taxonomic identification was made by Dr. Norazian
Mohd Hassan, a botanist at the Faculty of Pharmacy,
International Islamic University Malaysia (IIUM), Malaysia
against the voucher specimen with the reference number
of PIIUM-0201. The sample was also deposited in the
Herbarium of the Kulliyyah of Pharmacy, IIUM, Malaysia.
Drugs, chemicals, and reagents
The drugs used in the present study were glibenclamide
and streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO,
USA), while the chemicals used were ethanol, chloroform,
diethyl ether, formaldehyde, and paraffin wax (Merck,
Germany). All reagents used for serum biochemical
analysis were procured from Thermo Fisher Scientific
(VA, USA), while sodium carboxymethyl cellulose (Na
CMC) and citrate buffer were obtained from R & M
Chemicals (Canada). All chemicals and reagents used
were of analytical grade.
Plant material and extractions
Approximately 1.5 kg of mangosteen was obtained on
June 2012 from the local wet market in Kuantan, Pahang,
Malaysia. The pericarp was separated from its edible part
and washed with clean sterile water to remove surface pol-
lutants before being left to dry for 72 h at 37 °C in the la-
boratory drier (Memmert, Germany). The dried pericarp
was then pulverised to powder form using an electric
grinder and then further dried for another 24 h at room
temperature. The powdered sample was then subjected to
cold maceration in ethanol in the ratio of 4:1 (w:w) for
72 h at room temperature. The extracts were then filtered
and evaporated to dryness at 50 °C under reduced pressure
using the rotary evaporator (IKA, Germany) to yield a con-
centrated yellowish crude extract. The crude, dried ethano-
lic extract was subsequently stored at 2–8 °C until use.
Experimental animals
Healthy adult male Sprague–Dawley rats (weighed 150–
250 g; aged 16–19 weeks), obtained from the animal
house of the Faculty of Medicine and Health Science,
Universiti Putra Malaysia (UPM), Selangor, Malaysia,
were used in the present study. Upon arrival, the animals
were left to acclimatise for a week under laboratory con-
ditions in the animal laboratory, Faculty of Pharmacy,
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IIUM, Malaysia. Initial body weights were recorded a
day before the commencements of experiments. The rats
were randomly assigned to 6 equal groups (n = 6) and
housed separately in polypropylene cages. The animals
were kept under standard environmental conditions
(temperature 25 ± 2 °C, relative humidity 55 ± 10 %, and
12 h light/dark cycle) and were maintained under stand-
ard pellet diet and water ad libitum. All experiments
were performed in accordance with the current ethical
norms approved by the Institutional Animal Care and
Use Committee (IACUC), Integrated Centre for Re-
search Animal, Care & Use (ICRACU), IIUM, Malaysia
(Approval no.: IIUM/IACUC Approval/2013/(1)(1)).
Acute toxicity determination
The acute oral toxicity study was performed on healthy
Sprague–Dawley rats of both sexes, according to the Or-
ganisation for Economic Co-operation and Development
(OECD) Guideline no. 423. The rats were divided into
two groups (n = 6). Group 1 served as the control group
and received only vehicle, while Group 2 received fixed
dose of 2,000 mg/kg of GME. The rats were fasted over-
night before oral treatment of GME via force-feeding
method. Following the extract administration, the ani-
mals were continuously observed for three hours for any
changes in the autonomics and the general behavioural
and neurological profiles. The observations were contin-
ued for the subsequent 24 h in three-hour intervals for
mortality and daily for 14 days.
Experimental design
Hypoglycaemic activity of GME was assessed in the nor-
mal and STZ-induced diabetic rats via single-dose study,
while multiple-dose study was only performed on STZ-
induced diabetic rats. The test samples were suspended
in 0.2 % w/v Na CMC in distilled water. Glibenclamide
(0.5 mg/kg) was used as a reference drug (control posi-
tive group) during the study. All the test samples were
administered through oral route.
Single-dose study (acute antihyperglycaemic model)
Evaluation of GME effect on normoglycaemic rats
The rats were randomly assigned into 5 groups of six
animals each. Group 1 served as the normal control and
received only vehicle, while Group 2 that served as the
positive control group received 0.5 mg/kg glibenclamide.
On the other hand, Group 3, 4, and 5 were orally admin-
istered with GME at the dose of 50, 100, and 200 mg/kg,
respectively. All the rats were fasted for 16 h prior to
treatment, but allowed a free access to water before and
throughout the experiments. At the end of fasting
period, taken as zero time (0 h), blood glucose level was
measured by tail vein puncture at 1, 2, 4, and 8 h after
the sample administration.
Evaluation of GME effect on STZ-induced diabetic rats
Rats weighing 150–250 g were selected and fasted for
16 h prior to experiments and allowed an access to
water ad libitum. Experimental diabetes was induced by
freshly dissolved STZ (50 mg/kg, i.p.) in cold citrate buf-
fer (pH 4.5, 0.1 M). Diabetic rats were confirmed three
days after the STZ injection. The rats with the fasting
blood glucose of >250 mg/dL were considered diabetic
and included in the study. The rats were randomly
assigned into 5 groups of six animals each and then sub-
jected to the following treatments: Group 1 served as
diabetic control group and received only vehicle; Group
2 served as the positive control group and received
0.5 mg/kg glibenclamide; and Group 3, 4 and 5 received
the test extract at the dose of 50, 100, and 200 mg/kg,
respectively. All the test samples were administered in a
similar manner. Blood glucose level was estimated at the
interval of 1, 2, 4, and 8 h after the extract administra-
tion, respectively.
Multiple-dose study (subacute antihyperglycaemic model)
Evaluation of GME on STZ-induced diabetic rats
Diabetes mellitus was induced by a single intraperitoneal
injection of freshly prepared 50 mg/kg STZ dissolved in
0.1 M pH 4.5 cold citrate buffer in overnight-fasted rats
(16 h). Blood glucose level was estimated prior to the in-
jection of STZ and monitored for 24–72 h for confirm-
ation of diabetes. Only rats with hyperglycaemia (blood
glucose of >250 mg/dL) were included in the experi-
ments. The blood concentration of glucose in normal
rats should be within 80–110 mg/dL. The treatment
commenced 4 days after the STZ injection, which was
considered as Day 1 of treatment, and continued for an-
other 28 days. The rats were divided into the following
groups comprising six rats in each group:
Group 1: Normal control, received vehicle only.
Group 2: Diabetic control, received vehicle only.
Group 3: Diabetic rats, received 0.5 mg/kg glibencla-
mide (p.o.).
Group 4: Diabetic rats, administered with 50 mg/kg of
GME1 orally.
Group 5: Diabetic rats, administered with 100 mg/kg
of GME2 orally.
Group 6: Diabetic rats, administered with 200 mg/kg
of GME3 orally.
Blood collection
Overnight-fasted rats (16 h) were sacrificed by cervical
decapitation on Day 29 of the experiments following the
ethical norms granted by the ethics committee. The
trunk blood was collected in serum separation tubes
(BD Vacutainer® SST II), which contained clot activator.
Blood clot was removed by centrifugation at 2,000 × g
for 10 min in a refrigerated centrifuge CR4 22 (Jouan,
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France) at 4 °C. The resulting supernatant, designated as
serum, was transferred into a clean polypropylene tube
(Eppendorf, Germany) and maintained at 2–8 °C prior
to the analysis.
Biochemical analysis
The biochemical analysis was performed to measure the
serum level of triglycerides (TG), total cholesterol (TC),
high density lipoprotein (HDL), low density lipoprotein
(LDL), very low density lipoprotein (VLDL), serum glutamic
oxaloacetic transaminase (SGOT/AST), serum glutamic
pyruvic transaminase (SGPT/ALT), alkaline phosphatase
(ALP), urea, creatinine, and total protein (TP). Analytical
tests were performed via UV–vis spectrophotometer using
Konelab 20XTi (Thermo Fisher Scientific, USA).
Histopathological assessment
The animals were sacrificed, and their pancreatic tissue,
kidney, and liver were harvested and then fixed in 10 %
(v/v) neutral buffered formalin. The fixed tissues or
organs were then dehydrated and embedded in paraffin
wax before being sectioned to approximately 5 μm thick-
ness. Lastly, the sectioned tissues were stained with
haematoxylin and eosin followed by the histopathological
examinations.
Statistical analysis
All values were expressed as mean ± S.E.M. The one-way
analysis of variance (ANOVA) followed by the Tukey’s
post hoc test was used to statistically analyse the data
obtained when studying the single-dose effect of GME
on the normoglycaemic or STZ-induced diabetic rats.
On the other hand, the two-way ANOVA followed by
the Bonferroni’s post hoc test was used to statistically
analyse the data obtained when studying the multiple-
dose effect of GME on blood glucose and body weight in
the STZ-induced diabetic rats. The results were
considered statistically significant at p < 0.05. The statis-
tical package of IBM SPSS Statistics 21 for Windows
was used in the analysis.
Results
Acute toxicity study
GME-treated animals of both sexes did not show any al-
terations in their neurobehavioural patterns, health status,
or mortality at the fixed dose of 2,000 mg/kg. When com-
pared to vehicle-treated group, there were no significant
changes in the body weight and food intake. Hence, the
extract was suggested to be safe for consumption even at
the dosage of 2,000 mg/kg.
Effect of GME on normoglycaemic rats (single-dose study)
Figure 1 shows the effect of orally administered GME at
various doses on the blood glucose level in the normal
healthy rats. The blood glucose level of normal control
group was insignificantly maintained between 110 and
120 mg/dL, and pretreatment with 0.5 mg/kg glibencla-
mide significantly (p < 0.05) reduced the blood glucose
level starting 2 h after the drug administration. Pretreat-
ment with all doses of GME significantly (p < 0.05) re-
duced the blood glucose level starting 2 h (50 mg/kg
GME) or 1 h (100 and 200 mg/kg GME) after the extract
administration. The decrease in blood glucose level fol-
lowing the glibenclamide or GME administration was
found to continue until the end of experiment. The blood
glucose was expected to restore to normal after 8 h.
Effect of GME on STZ-induced diabetic rats (single-dose study)
Figure 2 presents the effect of orally administered GME
at various doses on the blood glucose levels in the STZ-
induced diabetic rats. Treatment with 0.5 mg/kg gliben-
clamide caused a significant (p < 0.05) decrease in the
blood glucose levels after 2 h of its administration. In
comparison to the diabetic control group (untreated),
Fig. 1 Effect of GME on normoglycaemic rats. Data are expressed as mean ± S.E.M. for six separate observations (n = 6); One-way ANOVA test
followed by Tukey’s post-hoc test was used to analyse the data; *significantly different (p < 0.05) when compared to the normal control
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the level continued to be lower until the end of experi-
ments (8 h). Treatment with GME was also able to sig-
nificantly (p < 0.05) reduce the blood glucose level at
200 mg/kg starting at the fourth hour after the extract
administration.
Effect of GME on blood glucose level and body weight
changes in STZ-induced diabetic rats (multiple-dose study)
Figures 3 and 4 respectively depict the subacute effect of
GME at various doses on the blood glucose level and
body weight changes in STZ-induced diabetic rats. The
diabetic control group demonstrated a significant (p <
0.05) increase in the blood glucose level starting from Day
1 while showing a significant (p < 0.05) decrease in their
body weight from Day 14 when compared to the normal
control group. Treatment with 0.5 mg/kg glibenclamide
caused a significant (p < 0.05) and gradual decrease in the
blood glucose level starting from Day 7 while significantly
(p < 0.05) increasing the body weight of rats starting from
Day 14 when compared to the diabetic control group. The
significant effect of glibenclamide on both parameters
continued to be seen until the end of experiment (Day
28). In the groups treated with GME, at all doses, a signifi-
cant (p < 0.05) reduction of blood glucose level, but an
increase in body weight changes, was observed on Day 14
until the end of experiment when compared to the dia-
betic control group. The decrease in glucose level by
GME occurred in a dose-independent manner.
Effect of GME on serum biochemical indices
Effect of GME on serum lipid profiles in STZ-induced
diabetic rats
Table 1 presents the effect of GME at various doses on
the serum lipid profiles in STZ-induced diabetic rats.
Fig. 2 Effect of GME on STZ-induced diabetic rats. Data are expressed as mean ± S.E.M. for six separate observations (n = 6); One-way ANOVA test
followed by Tukey’s post-hoc test was used to analyse the data; *significantly different (p < 0.05) when compared to the diabetic control
Fig. 3 Effect of GME on blood glucose level in STZ-induced diabetics rats for multiple-dose study. Each value is expressed as mean ± S.E.M. (n = 6). Data
analysis was performed by two-way ANOVA followed by Bonferroni’s post-hoc test. asignificantly different (p < 0.05) when compared to the normal
control group; bsignificantly different (p < 0.05) when compared to the corresponding values of the diabetic control group
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There was a significant (p < 0.05) increase in the level of
TG, TC, LDL, and VLDL in the diabetic control rats
when compared to the normal control group. Pretreatment
with GME or glibenclamide at all doses was found to sig-
nificantly (p < 0.05) reduce the level of TG, TC, LDL, and
VLDL in the STZ-induced diabetic rats.
Effect of GME on kidney, total protein, and liver enzymes in
STZ-induced diabetic rats
Table 2 shows the effect of GME at various doses on the
liver and kidney biochemical parameters in the STZ-
treated diabetic rats. With regard to the liver, the levels
of SGOT, SGPT, and ALP significantly (p < 0.05) in-
creased in the diabetic control rats when compared to
the normal control rats. Pretreatment of STZ-induced
diabetic rats with GME significantly (p < 0.05) reduced
the level of SGOT and SGPT, but not ALP. With regard
to the kidney, the diabetic control group showed a sig-
nificant (p < 0.05) increase in the level of urea and cre-
atinine, but there was a significant (p < 0.05) decrease in
the level of TP. All the biochemical parameters of the
kidney were significantly (p < 0.05) reversed after the
treatment with GME or glibenclamide.
Histopathological studies
At the end of the 28-day treatment, histopathological
assessment was carried out on the rats’ pancreas (see
Fig. 5). The microscopic analysis of liver tissue obtained
from the normal control group showed the presence of a
normal pancreatic tissue consisting of the normal acini,
normal cellular population, and absence of damaged
islets or hyperplasia. Tissue from the diabetic control
group demonstrated the presence of partial islets de-
struction with reduced size and observable flattening of
nuclei, which were pushed to the periphery. The tissue
obtained from glibenclamide-treated group revealed an
obvious improvement with the recovery of normal pan-
creatic histoarchitecture. As for the group treated with
GME, the tissue treated with 50 mg/kg GME showed
the restoration of normal cellular population size of is-
lets of Langerhans. The treatment also reduced the dam-
aged islets and decreased the presence of hyperplasia. As
Fig. 4 Effect of body weight in STZ-induced diabetic rats for 28 days of treatment. Each value is expressed as mean ± S.E.M. (n = 6). Data analysis
was performed by two-way ANOVA followed by Bonferroni’s post-hoc test. asignificantly different (p < 0.05) when compared to the normal control
group Day 1; bsignificantly different (p < 0.05) when compared to the normal control group of the respective tie interval; csignificantly different
(p < 0.05) when compared to the group treated with the respective test solution on Day 1; dsignificantly different (p < 0.05) when compared
to the diabetic control of the respective time interval
Table 1 Effect of GME at various doses on the serum lipid profiles in STZ-treated diabetic rats
Experimental group TG (mg/dL) TC (mg/dL) HDL (mg/dL) LDL (mg/dL) VLDL (mg/dL)
Normal control 85.00 ± 3.20 73.83 ± 4.35 15.50 ± 0.57 41.34 ± 4.45 17.00 ± 0.64
Diabetic control 219.5 ± 7.66* 133.5 ± 3.15* 11.46 ± 1.31 78.14 ± 4.61* 43.9 ± 1.53*
STZ + 0.5 mg/kg glibenclamide 104.17 ± 3.48** 71 ± 3.53** 20.26 ± 1.23** 29.91 ± 4.00** 20.83 ± 0.70**
STZ + 50 mg/kg GME 159.67 ± 5.23** 92 ± 2.32** 13.42 ± 1.28 46.65 ± 3.47** 31.93 ± 1.05**
STZ + 100 mg/kg GME 131.67 ± 5.37** 91.5 ± 2.17** 12.92 ± 1.02 52.25 ± 2.20** 26.33 ± 1.07**
STZ + 200 mg/kg GME 133.17 ± 3.40** 73.67 ± 4.06** 15.5 ± 1.20 31.53 ± 4.34** 26.63 ± 0.68**
*significantly different (p < 0.05) when compared to the normal control group of the respective column
** significantly different (p < 0.05) when compared to the diabetic control group of the respective column
Data are expressed as mean ± S.E.M. for six separate observations (n = 6); One-way ANOVA test followed by Tukey’s post-hoc test (p < 0.05) was used to analyse
differences among the selected lipid profiles
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for the group treated with 100 mg/kg GME, the tissue
showed the presence of granulated islets of Langerhans
with prominent hyperplasia. In the 200 mg/kg GME-
treated group, the tissue demonstrated the presence of
evenly distributed β-cells in an increase number and the
absence of damaged islets and hyperplasia.
Discussion
Diabetes mellitus is a metabolic disorder characterised
by derangement in carbohydrate, protein, and fat metabo-
lisms resulting from impairment in glucose homeostasis,
lack of insulin secretion, and development of macro- and
microvascular dysfunctions [23]. Modern antidiabetic
agents like sulphonylureas, thiazolidinediones, and bigua-
nides are commercially prescribed but failed to provide a
prolonged glycaemic control effect. Medicinal plants have
been widely used to treat diabetes due to their effective-
ness, safety, affordability, and acceptability. The present
study highlighted the potential hypoglycaemic action of
GME in normal and diabetic-induced rats. In this study,
diabetes was induced in the rats using 50 mg/kg STZ, a
glucosamine derivative of nitrosurea, which selectively de-
stroys pancreatic islets of β-cells and causes development
of hyperglycaemia and glycosuria, as seen in type 1 dia-
betic patients. Glibenclamide (glyburide), a member of the
second generation sulphonylureas, provides an effective
treatment for patients with moderate diabetes. Other than
its glucose-lowering properties, glibenclamide seems to
have antioxidant properties and is capable of restoring
liver antioxidant enzymes, superoxide dismutase (SOD),
and catalase (CAT) in STZ-induced diabetic rats [24]. The
increase in blood glucose level might be due to shortage
of insulin as a result of destruction of pancreas interceded
by STZ action, which boosts ATP dephosphorylation,
which in turn generates superoxide anions, hydrogen per-
oxide, and hydroxyl radicals. Elevated intracellular perox-
ides in pancreatic islets further mediate a damage induced
by reactive oxygen species (ROS) [25]. Under hypergly-
caemic conditions, antioxidants are supposed to regener-
ate damaged extracellular matrix proteins and cell growth
as a result of ROS elevation through nonenzymatic glyca-
tion of proteins, as well as through auto-oxidation [26].
This indication marks the increased levels of indicators of
oxidative stress in diabetic patients. Because oxidative
stress is associated with pathogenesis of diabetes, there-
fore, it can be postulated that the antioxidants may exert a
key role in the management of DM.
Mangosteen’s pericarps, leaves, and barks have been
used traditionally to treat various ailments such as arthritis,
diarrhoea, dysentery, inflammation, and skin disorders, be-
sides being applied in the healing of wound [27]. However,
no study has addressed its hypoglycaemic effect although it
has been commercially claimed as an antidiabetic agent.
To date, numerous articles have reported the use of
in vitro assays to evaluate the pharmacological effect of G.
mangostana’s purified compounds mainly α-mangostin,
which is the major bioactive secondary metabolite of
xanthone derivatives [28] and the first substance to be
isolated [29]. There are limited animal models testing on
α-mangostin, which could be attributed to its low bioavail-
ability via oral treatment when compared to the i.v.
administration [28]. Although there is an issue of low bio-
availability when α-mangostin is given orally, GME is still
given orally and tested in diabetic animal models as its
beneficial bioactive components consist of not only pure
conjugated xanthones, but also a combination of free and
unconjugated compounds [30]. This combination, as far as
the pharmacokinetic is concerned, can improve the bio-
availability of GME. This fact could be one of the best evi-
dences of better health-promoting properties of the extract
over the administration of pure compounds like xanthones.
Furthermore, the extract has been reported to exhibit α-
glucosidase inhibitory activity, which has been proven to
reduce postprandial hyperglycaemia by inhibiting glucose
absorption [31]. Moreover, the ethanol extract of G.
mangostana also shows a significant hypoglycaemic effect
following the oral maltose administration [20], and the
effect is similar to the reference drug, acarbose [32].
In this study, for the normoglycaemic rats, significant
blood glucose-lowering actions were observed in GME-













Normal control 22.5 ± 2.46 64.5 ± 6.25 74.78 ± 5.40 22.5 ± 2.07 0.81 ± 0.03 7.12 ± 0.15
Diabetic control 76 ± 5.73* 159.5 ± 7.08* 173.5 ± 15.51* 143.7 ± 7.57* 1.25 ± 0.13* 5.05 ± 0.24*
STZ + 0.5 mg/kg glibenclamide 38.17 ± 3.62** 66.83 ± 5.46** 147.83 ± 15.90 54.25 ± 3.46** 0.99 ± 0.04 7.85 ± 0.24**
STZ + 50 mg/kg GME 87.5 ± 12.46 137.83 ± 6.28 156.67 ± 13.19 135.3 ± 3.86 0.84 ± 0.07** 6.15 ± 0.26**
STZ + 100 mg/kg GME 52 ± 3.91** 125.33 ± 6.86** 149.5 ± 11.84 96.6 ± 2.28** 0.98 ± 0.07 6.75 ± 0.13**
STZ + 200 mg/kg GME 56.17 ± 5.43** 148.5 ± 12.16 157.83 ± 14.91 105.77 ± 4.05** 0.87 ± 0.041** 6.72 ± 0.14**
*significantly different (p < 0.05) when compared to the normal control group of the respective column
** significantly different (p < 0.05) when compared to the diabetic control group of the respective column
Data are expressed as mean ± S.E.M. for six separate observations (n = 6); One-way ANOVA test followed by Tukey’s post-hoc test (p < 0.05) was used to analyse
differences among the selected kidney’s profiles
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and glibenclamide-treated groups when compared to the
normal control group. The effect of GME on normogly-
caemic animals suggests that the pericarp of G. mangos-
tana has a mild lowering effect on normal glucose
levels. This effect was comparable to that of glibencla-
mide, an insulin secretagogue, which also lowers blood
glucose in normal animals. Provided the β-cells are fully
functional, sulphonylureas such as glibenclamide can
cause hypoglycaemia because insulin release is initiated
even when glucose concentrations are below the normal
threshold for glucose-stimulated insulin release (approxi-
mately 5 mmol/L or 90 mg/dL) [33]. In the same study on
STZ-induced rats, we reported the increase of
hypoglycaemic action of glibenclamide and GME in a
dose-dependent manner. This was indicative of the po-
tentiation of GME on insulin secretion and the enhanced
peripheral utilisation of insulin in diabetic rats as sup-
ported by the histopathological findings. Glibenclamide
was used as a reference hypoglycaemic agent to compare
the efficacy of a variety of glucose-reducing compounds
via enhanced activity of β-cells of the pancreas resulting in
the secretion of larger amounts of insulin. In the multiple-
dosage study, the elevated blood glucose improved after
28 days of GME treatment, suggesting that the extract’s
Fig. 5 Photomicrograph of pancreatic islets of experimental rats after 28 days of treatment. a Normal control: Depicted typical rat pancreas with
blood capillaries surrounded by centroacinar cells which contain serous acini. b Diabetic control: Observable necrosis and degranulation of serous
acini resulted in diminished number of β-cells and islets size. c STZ-glibenclamide: Granulated islets, hyperplasia and restoration of normal
cytoarchitecture with regeneration of pancreatic islets. d STZ-GME1: Exocrine region and islets of Langerhans, with scattered β-cells and
visible red blood cells. e STZ-GME2: Hyperplasia, granulated islets and mild expansion of pancreatic islets. f STZ-GME3: Evenly distributed
and increased number of β-cells with moderate rejuvenated pancreatic islet. (All samples were stained with haematoxylin and eosin,
original magnification × 400)
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antioxidant activity mediated the protective effect of
β-cells in the diabetic rats. It is widely accepted that
the enhancement of antioxidant activity could be one
of the mechanisms responsible in the prevention of
diabetic complications [34].
The STZ-induced rats initially showed a reduction in
their body weight, suggesting abnormal water and food
intake. However, the administration of GME in diabetic
rats improved their weight commencing from Day 14
onwards in comparison to the diabetic control group.
The increase in body weight could be due to amelior-
ation of glycaemic control and structural proteins syn-
thesis [35]. This finding was actually contradicting the
finding made by Chivapat et al. [36], who reported that
GME at the dose of 1,000 mg/kg or above caused reduc-
tion in the body weight of male rats. This observation
was related to the effect of condensed tannins in the ex-
tract of G. mangostana pericarp [37] that are believed to
be present in a high quantity due to the high dose
(1,000 mg/kg) of GME used [36]. In other studies, the
mice fed with a diet containing tannic acid underwent a
growth retardation [38], while those fed with a high dose
of tannins suffered from a slower growth rate when
compared to the mice that consumed a low dose of tan-
nins [39]. It is plausible to suggest that the amount of
condensed tannins present in the GME at the dose of
50–200 mg/kg as used in the present study was not
enough to trigger body weight reduction. In addition,
weight loss in the diabetic rats could be the result of
high catabolic rate of protein to amino acid for gluco-
neogenesis during insulin deficiency, which could be
enhanced in the presence of enough concentration of
tannins [39]. In the present study, the lack of protein
catabolism could be related to the insufficient amount of
condensed tannins present in the GME.
The high cholesterol and lipid levels mark an increased
risk of atherosclerosis and coronary heart diseases devel-
opment, which are considered secondary complications of
diabetes [40, 41]. In the present study, GME was found to
reduce the total cholesterol and triglycerides in STZ-
treated rats, suggesting the extract’s capability to reduce
atherogenic-related complications. Liver plays a crucial
function in the metabolism, storage, detoxification, and
excretion of xenobiotics and their metabolites. Liver func-
tion tests provide vital indicators of liver activities, which
include SGOT, SGPT, and ALP [42]. High levels of these
enzymes in the blood indicated leakage from the liver
cytosol into the bloodstream, indicating a liver injury [42].
In the present study, GME reduced the levels of important
liver enzymes, particularly SGOT and SGPT, in all the
treated groups. Because of the promising reduction of liver
transaminases, long-term studies should be conducted to
observe the improvement of liver function markers fol-
lowing the consumption of GME. It is important to
highlight that the effect of GME on the level of liver en-
zymes was observed in a dose-independent manner with
the maximum reduction observed at the dose of 100 mg/
kg. This observation could be associated with the
phenomenon known as “therapeutic windows” [43], which
could possibly be related to the optimal hepatoprotective
effect of GME or reduction in the enzyme activity. Other
than that, GME was also observed to cause an increase in
the urea and creatinine levels, which were reduced in the
diabetic groups. The ability of diabetic rats to decrease
both parameters seems to suggest that diabetes could lead
to renal dysfunction. The significant improvement in the
level of renal markers indicated the potential of GME to
ameliorate the kidney dysfunction. Additionally, the total
protein content was also found to improve in the diabetic
rats following a treatment with GME, suggesting the re-
medial role of the extract towards the kidney function in
the diabetic rats. Histopathological examination revealed
an improved preservation of normal pancreatic islets and
diminished necrotic changes as compared to the STZ-
induced diabetic rats. The effect of GME might be due to
the pancreatic rejuvenation via enhanced protein synthe-
sis, accelerated detoxification, potentiation of antioxidant
defence, and neutralisation of free radicals, which
confirmed the insulinotropic effect of GME through
the regeneration of insulin-producing β-cells.
The hypoglycaemic activity of GME could also be
attributable to the extract’s phytoconstituents. Polyphe-
nolics like tannins have been reported to be present in
the pericarp of G. mangostana [44]. In addition, several
polyphenols have been identified from the pericarp
namely 4-aryl-2-flavanylbenzopyran derivative, 3,4,3′,5’-
tetrahydroxy-5-methoxybenzophenone, 2,3-dihydrochro-
mone derivative, epicatechin, and procyanidin B2 [45].
Previous studies have also reported the presence of various
types of xanthones in different parts of G. mangostana,
including the pericarp. Some of the identified xanthones
derived from pericarp are mangostinone, α-mangostin,
β-mangostin, γ-mangostin, gartanin, garcinone E, 1,5-
dihydroxy-2-(3-methylbut-2-enyl)-3- methoxyxanthone,
1,7-dihydroxy-2-(3-methylbut-2-enyl)-3-methoxyxanthone
[46], 8-hydroxycudraxanthone G, mangostingone, cudrax-
anthone G, 8-deoxygartanin, garcimangosone B, garcinone
D, garcinone E, gartanin, 1-isomangostin, mangostinone,
smeathxanthone A, tovophyllin A, mangostanaxanthones I,
mangostanaxanthones II, 9-hydroxycalabaxanthone, parvifo-
lixanthone C, rubraxanthone [47], 1,3,7-trihydroxy-2-(3-
methyl-2-butenyl)-8-(3-hydroxy-3-methylbutyl)-xanthone,
1,3,8-trihydroxy-2-(3-methyl-2-butenyl)-4-(3-hydroxy-3-
methylbutanoyl)-xanthone, garcinones C, garcinones D,
gartanin, xanthone I [48], garcimangosxanthone F (1),
garcimangosxanthone G [49], and mangostanate [50].
The presence of xanthones and polyphenols like tan-
nins in the pericarp of G. mangostana could also be used
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to explain the hypoglycaemic activity of GME observed.
Tannins, one of the major groups of antioxidant poly-
phenols, can be classified into two broad groups namely
hydrolysable tannins and condensed tannins. Hydrolys-
able tannins are molecules with a polyol (D-glucose) as a
central core. The hydroxyl groups of these carbohydrates
are partially or totally esterified with phenolic groups
(i.e., gallic acid or ellagic acid). Hydrolysable tannins are
usually present in low amounts in plants and are easily
hydrolysed by mild acids and bases to yield carbohydrate
and phenolic acids. Condensed tannins are a group of
naturally occurring polyphenolic bioflavonoids, specific-
ally taking the form of oligomers or polymers of polyhy-
droxy flavan-3-ol units such as (+)-catechin and
(−)-epicatechin. Condensed tannins are more common
in the plant kingdom and have been reported to have a
wide range of biological and pharmacological activities
including antioxidative activity without inducing signifi-
cant toxicological effects [51]. These protective effects
are related to their capacity (a) to act as free radical
scavengers and (b) to stimulate antioxidant enzymes.
Moreover, tannins have been observed to improve the
glucose uptake through mediators of the insulin-signalling
pathways (i.e., phosphoinositide 3-kinase (PI3K) and
mitogen-activated protein kinase (p38 MAPK) activations
and GLUT-4 translocation. The reduction in glycaemia
(blood glucose levels) caused by tannins and other phen-
olic compounds has been attributed to actions such as (a)
a decrease in the absorption of nutrients (b) a decrease in
food intake (c) initiation of β-cell regeneration, (d) direct
action on adipose cells that enhances insulin activity, and
(e) sharing insulin-signalling pathways in hepatocytes pos-
sibly by modulation of the redox state of cell [51]. In other
words, tannins work to establish an organised network of
metabolic sensors that incorporates glucose homeostasis,
lipid metabolism, inflammation, drug metabolism, bile
acid synthesis, and some other processes. One of the re-
storative approaches to decrease postprandial hypergly-
caemia is by preventing or delaying the absorption of
glucose via inhibition of carbohydrate hydrolysing en-
zymes, α-amylase, and α-glucosidase in the digestive or-
gans. Interestingly, tannins are natural inhibitors of α-
amylase and α-glucosidase with a potent inhibitory effect
on the latter, but a mild inhibitory effect on the former.
Therefore, phenolic antioxidant-mediated inhibition of
these enzymes can significantly decrease the postprandial
hyperglycaemia after ingestion of a mixed carbohydrate
diet and could be an effective strategy in the control of
diabetes [51]. Epicatechin, one of the natural condensed
tannins present in G. mangostana pericarp [45], prevents
hyperglycaemia by inducing β-cell regeneration [52]. This
effect of epicatechin is supported by the histopathological
examination of the rat’s liver tissue treated with GME in
comparison to the tissue of diabetic rats. Taking other
reports into consideration, several other possible
mechanisms of hypoglycaemic condition could also be
suggested to be triggered by tannins in order to in-
duce hypoglycaemia, and these mechanisms include
(a) reduction in food intake, (b) inhibition of intestinal
glucose absorption, and (c) direct action on adipose cells
by enhancing insulin activity in rat epididymal adipocytes.
Catechins are powerful antioxidants that inhibit oxidation
of LDL-cholesterol, reduce cholesterol levels, and reduce
body fat, resulting in a decreased risk of heart disease.
Other than that, several xanthones have also been re-
ported to exert antihyperglycaemic activity. According to
Jariyapongskul et al. [53], the damage in the retinal mi-
crovasculature in type 2 diabetic rat model such as re-
duction of ocular blood flow (OBF) and leakage of the
blood-retinal barrier (BRB) permeability is associated
with hyperglycaemia and the accumulations of free radi-
cals, advanced glycation end products (AGEs), receptor
of advanced glycation end products (RAGE), tumour ne-
crosis factor alpha (TNF-α), and vascular endothelial
growth factor (VEGF) levels in the retinal tissues. α-
Mangostin has also been reported to prevent retinal
microvascular complications in diabetic rats possibly via
its antihyperglycaemic, antioxidant, anti-inflammatory,
and antiglycation properties [53]. Other xanthone, man-
giferin reduces the level of blood glucose by increasing
the level of insulin in STZ-induce diabetic rats. More-
over, mangiferin also increases the level of hexokinase,
pyruvate kinase, glucose-6-phosphate dehydrogenase,
glycogen synthase, and glycogen content to near normal
in diabetic rats. The levels of these enzymes are reduced
following a treatment with STZ. On the other hand, the
activities of lactate dehydrogenase, glucose-6-phosphatase,
fructose-1,6-diphosphatase, and glycogen phosphorylase
in the liver tissue of diabetic rats are decreased after a
treatment with mangiferin [54]. Besides, mangiferin has
also been shown to exert an antidiabetic activity in KK-Ay
mice (an animal model of type-2 diabetes) by decreasing
insulin resistance [55]. Moreover, several xanthones iso-
lated from the fruit case of G. mangostana have also been
reported to exert α-glucosidase inhibitory activity [56].
Conclusion
The ethanolic extract of G. mangostana pericarp exerts
hypoglycaemic and antidiabetic activities possibly by in-
creasing the population of insulin-producing β-cells.
This observation could further be attributed to the pres-
ence of antioxidant-bearing tannins like epicathecin and
xanthones like α-mangostin that might act synergistically
to exert the effect. Thus, the finding demonstrated that
GME could be a potential candidate in the management
of diabetes owing to its hypoglycaemic and thus antidia-
betic effects. Therefore, further studies are required to
elucidate the mechanism of action involved.
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